An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
一项开放标签的 II 期临床试验,旨在评估 sotrovib (VIR-7831) 预防 COVID-19 感染在免疫功能低下且 SARS-CoV-2 体液免疫受损个体中的疗效。
期刊:New Microbes and New Infections
影响因子:5.4
doi:10.1016/j.nmni.2025.101620
Gonzalez-Bocco, Isabel H; Frierson, Rayven; Cho, Alyssa; Reyes Curcio, Fabiola A; Franceschi, Andres E; Lahoud, Chloe; Moshovitis, Dimitrios G; Beluch, Katherine; Balusu, Manu; Keleher, C Elizabeth; Sullivan, Keri M; Dougan, Michael; Wang, Qianwen; Han, Jennifer H; Nader, Ahmed; Aylott, Alicia; Wang, Wei; Chan, Brian T; Hammond, Sarah P; Manne-Goehler, Jennifer; Koo, Sophia